|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: REXO2 |
Gene summary for REXO2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | REXO2 | Gene ID | 25996 |
| Gene name | RNA exonuclease 2 | |
| Gene Alias | CGI-114 | |
| Cytomap | 11q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9Y3B8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25996 | REXO2 | AEH-subject1 | Human | Endometrium | AEH | 6.04e-09 | -3.35e-01 | -0.3059 |
| 25996 | REXO2 | AEH-subject2 | Human | Endometrium | AEH | 6.32e-06 | -3.14e-01 | -0.2525 |
| 25996 | REXO2 | AEH-subject3 | Human | Endometrium | AEH | 3.64e-06 | -2.64e-01 | -0.2576 |
| 25996 | REXO2 | AEH-subject4 | Human | Endometrium | AEH | 1.44e-04 | -2.40e-01 | -0.2657 |
| 25996 | REXO2 | AEH-subject5 | Human | Endometrium | AEH | 7.18e-07 | -3.75e-01 | -0.2953 |
| 25996 | REXO2 | EEC-subject1 | Human | Endometrium | EEC | 6.04e-09 | -3.46e-01 | -0.2682 |
| 25996 | REXO2 | EEC-subject2 | Human | Endometrium | EEC | 4.75e-12 | -3.48e-01 | -0.2607 |
| 25996 | REXO2 | EEC-subject3 | Human | Endometrium | EEC | 4.23e-25 | -2.70e-01 | -0.2525 |
| 25996 | REXO2 | EEC-subject4 | Human | Endometrium | EEC | 4.42e-05 | -2.74e-01 | -0.2571 |
| 25996 | REXO2 | EEC-subject5 | Human | Endometrium | EEC | 4.53e-06 | -3.08e-01 | -0.249 |
| 25996 | REXO2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.41e-20 | -3.66e-01 | -0.1869 |
| 25996 | REXO2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 3.36e-23 | -3.65e-01 | -0.1875 |
| 25996 | REXO2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.00e-26 | -4.27e-01 | -0.1883 |
| 25996 | REXO2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 7.02e-31 | -2.72e-01 | -0.1934 |
| 25996 | REXO2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.17e-41 | -3.57e-01 | -0.1917 |
| 25996 | REXO2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 3.96e-32 | -4.56e-01 | -0.1916 |
| 25996 | REXO2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 8.69e-04 | -2.42e-01 | -0.1269 |
| 25996 | REXO2 | LZE4T | Human | Esophagus | ESCC | 3.61e-09 | 3.88e-01 | 0.0811 |
| 25996 | REXO2 | LZE8T | Human | Esophagus | ESCC | 4.18e-03 | 9.53e-02 | 0.067 |
| 25996 | REXO2 | LZE20T | Human | Esophagus | ESCC | 1.29e-03 | 3.49e-01 | 0.0662 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000911715 | Endometrium | AEH | nucleotide metabolic process | 78/2100 | 489/18723 | 8.39e-04 | 7.82e-03 | 78 |
| GO:000675314 | Endometrium | AEH | nucleoside phosphate metabolic process | 78/2100 | 497/18723 | 1.34e-03 | 1.13e-02 | 78 |
| GO:000911716 | Endometrium | EEC | nucleotide metabolic process | 80/2168 | 489/18723 | 8.65e-04 | 7.95e-03 | 80 |
| GO:000675315 | Endometrium | EEC | nucleoside phosphate metabolic process | 80/2168 | 497/18723 | 1.39e-03 | 1.14e-02 | 80 |
| GO:000911720 | Esophagus | HGIN | nucleotide metabolic process | 92/2587 | 489/18723 | 1.11e-03 | 1.36e-02 | 92 |
| GO:000675320 | Esophagus | HGIN | nucleoside phosphate metabolic process | 93/2587 | 497/18723 | 1.25e-03 | 1.49e-02 | 93 |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:00905033 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, exonucleolytic | 35/8552 | 42/18723 | 5.35e-07 | 7.11e-06 | 35 |
| GO:000675312 | Liver | Cirrhotic | nucleoside phosphate metabolic process | 190/4634 | 497/18723 | 1.10e-11 | 6.96e-10 | 190 |
| GO:000911712 | Liver | Cirrhotic | nucleotide metabolic process | 187/4634 | 489/18723 | 1.55e-11 | 9.63e-10 | 187 |
| GO:0090501 | Liver | Cirrhotic | RNA phosphodiester bond hydrolysis | 54/4634 | 152/18723 | 1.89e-03 | 1.19e-02 | 54 |
| GO:0090503 | Liver | Cirrhotic | RNA phosphodiester bond hydrolysis, exonucleolytic | 19/4634 | 42/18723 | 3.00e-03 | 1.71e-02 | 19 |
| GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
| GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
| GO:00905011 | Liver | HCC | RNA phosphodiester bond hydrolysis | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
| GO:00905031 | Liver | HCC | RNA phosphodiester bond hydrolysis, exonucleolytic | 29/7958 | 42/18723 | 4.57e-04 | 3.04e-03 | 29 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| REXO2 | SNV | Missense_Mutation | c.229G>C | p.Glu77Gln | p.E77Q | Q9Y3B8 | protein_coding | tolerated(0.18) | benign(0.023) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| REXO2 | SNV | Missense_Mutation | rs539159879 | c.632N>A | p.Arg211Gln | p.R211Q | Q9Y3B8 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-BH-A0B9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| REXO2 | insertion | Frame_Shift_Ins | novel | c.335dupA | p.Ser113GlufsTer11 | p.S113Efs*11 | Q9Y3B8 | protein_coding | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| REXO2 | SNV | Missense_Mutation | c.533N>A | p.Arg178His | p.R178H | Q9Y3B8 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| REXO2 | insertion | Frame_Shift_Ins | novel | c.648_649insA | p.Ile219AsnfsTer3 | p.I219Nfs*3 | Q9Y3B8 | protein_coding | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| REXO2 | SNV | Missense_Mutation | novel | c.177N>T | p.Gln59His | p.Q59H | Q9Y3B8 | protein_coding | tolerated(0.67) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| REXO2 | SNV | Missense_Mutation | novel | c.34N>T | p.Arg12Trp | p.R12W | Q9Y3B8 | protein_coding | deleterious_low_confidence(0) | benign(0.097) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| REXO2 | SNV | Missense_Mutation | novel | c.377N>T | p.Ser126Phe | p.S126F | Q9Y3B8 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| REXO2 | SNV | Missense_Mutation | rs539159879 | c.632G>A | p.Arg211Gln | p.R211Q | Q9Y3B8 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| REXO2 | SNV | Missense_Mutation | c.605N>G | p.Glu202Gly | p.E202G | Q9Y3B8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |